Carl Zeiss Meditec Stock Total Debt
| CZMWF Stock | USD 59.30 4.43 8.07% |
Carl Zeiss Meditec fundamentals help investors to digest information that contributes to Carl Zeiss' financial success or failures. It also enables traders to predict the movement of Carl Pink Sheet. The fundamental analysis module provides a way to measure Carl Zeiss' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Carl Zeiss pink sheet.
Carl |
Carl Zeiss Meditec Company Total Debt Analysis
Carl Zeiss' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Carl Zeiss Total Debt | 120.05 M |
Most of Carl Zeiss' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Carl Zeiss Meditec is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Carl Zeiss Meditec has a Total Debt of 120.05 M. This is 95.64% lower than that of the Healthcare sector and 89.63% lower than that of the Medical Instruments & Supplies industry. The total debt for all United States stocks is 97.74% higher than that of the company.
Carl Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Carl Zeiss' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Carl Zeiss could also be used in its relative valuation, which is a method of valuing Carl Zeiss by comparing valuation metrics of similar companies.Carl Zeiss is currently under evaluation in total debt category among its peers.
Carl Fundamentals
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0955 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 12.07 B | |||
| Shares Outstanding | 89.44 M | |||
| Shares Owned By Insiders | 59.10 % | |||
| Shares Owned By Institutions | 22.23 % | |||
| Price To Earning | 75.63 X | |||
| Price To Book | 6.17 X | |||
| Price To Sales | 6.34 X | |||
| Revenue | 1.9 B | |||
| Gross Profit | 1.13 B | |||
| EBITDA | 419.49 M | |||
| Net Income | 293.91 M | |||
| Cash And Equivalents | 8.4 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 120.05 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 3.35 X | |||
| Book Value Per Share | 22.53 X | |||
| Cash Flow From Operations | 188.2 M | |||
| Earnings Per Share | 2.93 X | |||
| Price To Earnings To Growth | 3.93 X | |||
| Target Price | 138.8 | |||
| Number Of Employees | 4.22 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 12.53 B | |||
| Total Asset | 2.4 B | |||
| Retained Earnings | 458 M | |||
| Working Capital | 573 M | |||
| Current Asset | 859 M | |||
| Current Liabilities | 286 M | |||
| Z Score | 62.4 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 2.4 B | |||
| Last Dividend Paid | 1.1 |
About Carl Zeiss Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Carl Zeiss Meditec's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Carl Zeiss using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Carl Zeiss Meditec based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in Carl Pink Sheet
Carl Zeiss financial ratios help investors to determine whether Carl Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Carl with respect to the benefits of owning Carl Zeiss security.